Vivo Bio Tech Faces Financial Adjustments Amid Mixed Performance Indicators

Vivo Bio Tech, a microcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an evaluation adjustment that reflects notable shifts in its financial metrics. The company's financial performance for the quarter ending March 2025 has been characterized as flat, leading to a revision in its score. Over the past three months, the score has seen a decline, indicating a change in the company's financial standing.
On a positive note, Vivo Bio Tech reported a higher profit after tax (PAT) of Rs 7.11 crore for the nine-month period, alongside the lowest debt-equity ratio at 0.69 times, which suggests a manageable level of debt. Additionally, net sales for the quarter reached a peak of Rs 12.29 crore.

Conversely, challenges persist, particularly with cash and cash equivalents, which have dropped to Rs 1.28 crore, and the operating profit to net sales ratio, which stands at 40.85%. These factors contribute to the overall assessment of the company's financial health.

In terms of valuation, Vivo Bio Tech has been categorized as very attractive, with a price-to-earnings (PE) ratio of 9.60 and a price-to-book value of 0.90, indicating a favorable valuation compared to its peers.

For more insights on Vivo Bio Tech's financial trend performance, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.